International Science Review 1(1), 2020 **ISSN 2693-0315**

Coronavirus Pathogenesis and the Emerging Pathogen Severe Acute Respiratory Syndrome

Ayushi Chaudhary*
Harjeet Singh
Molecular genetic laboratory CG& B Division, ICAR- Central Institute Research on Cattle, India
Kush Bhatia
Megha Sirohi
Department of Biotechnology & Microbiology, Meerut Institute of Engineering & Technology, India
Umesh Singh
Molecular genetic laboratory CG& B Division, ICAR- Central Institute Research on Cattle, India
*Corresponding Author: ayushichaudhary9502@gmail.com
https://sriopenjournals.com/index.php/international_science_review/index

Citation: Chaudhary, A., Singh, H., Bhatia, K., Sirohi, M. & Singh, U. (2020). Coronavirus Pathogenesis and the Emerging Pathogen Severe Acute Respiratory Syndrome, *International Science Review*, 1(1), 6-20.

Research Article

Abstract

COVID-19, the ailment brought about by SARS-CoV-2, is an exceptionally infectious illness. The World Health Organization has proclaimed the progressing episode to be a worldwide general wellbeing crisis. Right now, the exploration of SARS-CoV-2 is in its essential stages. In view of the currently distributed proof, this audit methodically sums up the study of disease transmission, clinical attributes, findings, treatment, and anticipation of COVID-19. It is trusted that this survey will assist the general population in recognizing and managing SARS-CoV-2, and it will serve as a reference for future investigations.

Keywords: Pathogenesis, hydroxy chloroquinine, glycoprotein, SARS-CoV, single-stranded, envelope, classification, leverpectin, replication, nucleocapsid.

1. Introduction

The name corona refers to the form of the viruses. Coronaviruses are known to cause disease in humans, other mammals, and birds. It is an important form of pathogen for humans and animals. At the end of 2019 coronavirus was found as the cause of a cluster of pneumonia cases in Wuhan a city in the Hubei China. Coronavirus is rapidly spreading all over the world. In February 2020, the World Health Organization designated the disease COVID-19 in Co; stands for Corona, VI; stands for Virus, D: Disease, 19: 2019.

In humans, they are responsible for the respiratory and enteric disease. As a group, coronavirus is not limited to particular organs; target tissue including the nervous system, immune system, kidney, and reproductive tract in addition to many parts of the respiratory and enteric systems. Coronavirus is not new; it is a large family of virus whereas it is first identified in the 1960s which get their name from the crown-like spikes seen on their surface with electron microscopy. They can cause very mild symptoms like cold, fever, headache, body pain. There are many coronaviruses in which some found in humans and animals. Therefore a virus infects humans may also evolve to infect animals. In 2002 virus causing disease Severe Acute Respiratory

Syndrome (SARS) came from civets cat had a fatality rate of 10% and causing Middle Eastern Respiratory Syndrome (MERS).
Therefore rapid economic growth in Southern China has led to increasing demand for animal proteins including those from out of the ordinary food animals such as civets suggested by(Vincent C.C. Cheng; 2007). Large numbers of these varieties of animals overcrowded cages and lack of biosecurity measures in the wet market which allowed the jumping of the novel virus from animal to human. This virus can rapidly be transmitted from person to person. For this virus in 90s, 8,000 people were affected with a crude fatality rate 10% whereas the acute and dramatic impact on healthcare systems, economies, and societies of affected countries within a few months (Susanna K. P. Lau and Yung Yan, China 2007).

2. Classification, virology and genomic structure of SARS-CoV

2.1 Structure Of SARS-CoV-2

SARS CoV-2 infection is a beta coronavirus which was found in Wuhan City, Hubei Province, China in December 2019. They are encompassed, positive-sense, single-stranded RNA infections of zoonotic starting point. They are circular to pleomorphic particles, estimating somewhere in the range of 80 and 160 nm long. SARS CoV-2 contains four auxiliary proteins, to be specific envelope (E), spike (S), layer (M), and nucleocapsid (N). The S, M, and E proteins together structure the envelope of the infection. The M protein is the most inexhaustible, for the most part, answerable for the state of the envelope. The E protein is the littlest auxiliary protein. The S and M proteins are likewise the transmembrane proteins that are engaged with the infection get together during replication. N proteins remain related to the RNA shaping a nucleocapsid inside the envelope. Although N protein is to a great extent associated with forms identifying with the viral genome, it is additionally engaged with different parts of the CoV replication cycle (gathering and growing) and the host cell reaction to viral disease. Polymers of S proteins stay implanted in the envelope giving it a crown-like appearance, in this manner the name coronavirus.



Fig1. This picture shows the structure of SARS-CoV and the significant difference between Target Regions for SARS-CoV-2 testing *(Eleanore Dougherty; PerkinElmer 2020)*

2.2 Genome organization of SARS-CoV-2:

The genome of SARS-CoV-2 is a single-stranded positive-sense RNA of 30kb (29891 nucleotides) encoding 9860 amino acids. The G + C content is 38%. There are 12 functional open reading frames (ORFs) along with a set of nine subgenomic mRNAs carrying a conserved leader sequence, nine transcription-regulatory sequences, and 2 terminal untranslated regions. The genome of this virus lacks the haemagglutinin-esterase gene, which is characteristically found in lineage a β-CoV. Two-thirds of viral RNA, mainly located in the first ORF translates two polyproteins, pp1a and pp1ab, and encodes 16 non-structural proteins (NSP), while the remaining ORFs encode accessory and structural proteins. The 16 non-structural proteins include two viral cysteine proteases, namely, NSP3 (papain-like protease) and NSP5 (main protease), NSP12 (RNA-dependent RNA polymerase, NSP13 (helicase), and other NSPs which are likely involved in the transcription and replication of the virus. The rest part of the viral genome codes for four structural proteins E, M, S, and E along with a number of accessory proteins that interfere with the host immune response.



Fig. 2. Show Coronavirus Taxonomic Classification

The association of the coronavirus genome is 5'-pioneer UTR-replicase-S (Spike) – E (Envelope) - M (Membrane) - N (Nucleocapsid) - 3'UTR-poly (A) tail with extra qualities sprinkled inside the

auxiliary qualities at the 3′ end of the genome.SARS-CoV-2 is nearer to the SARS-like bat CoVs regarding the entire genome arrangement. However, mutations are observed in NSP2 and NSP3 and the spike protein that plays a significant role in the infectious capability and differentiation mechanism of SARS-CoV-2. Besides, two strains, namely L-type and S-type, are discovered. The L-type, derived from the S-type, is found to be more aggressive and contagious. Coronavirus belongs to the family coronaviridae within the order of Nidovirales, and is enveloped positive-sense single-stranded RNA virus. Members of coronaviridae are known to cause respiratory or Intestinal infections in humans and animals. They are round and sometimes poleiomorphic with 18-20nm in diameter. The coronavirus genome size around 31kb which formed these viruses the largest known RNA viruses yet identified. There are now 7 types of coronavirus that have been known by CDC. Human common coronavirus- 229 E (Alpha coronavirus), NL63 (Alpha coronavirus), OC43 (Beta coronavirus), HKU1 (Beta coronavirus) Other Human coronavirus- MERS –Cov (the beta coronavirus that causes the Middle East respiratory
syndrome), SARS- Cov (the beta coronavirus that causes a severe acute respiratory syndrome), Novel coronavirus 2019(SARS – Cov-2).Therefore the proteins play a crucial role to facilitate fusion of viral and host cell membranes is called Class I fusion protein (Kielian and Rey 2006). They are distinguished in class II fusion protein (Kielian 2006).

3. Coronavirus Replication

Following the discharge and uncoating of viral nucleocapsid to the cytoplasm, CoV replication starts with the interpretation of ORF 1a and 1b into polyproteins pp1a (4382 amino acids) and pp1ab (7073 amino acids). Here, the downstream ORF1b is interpreted through ribosomal frameshifting instrument, in which an interpreting ribosome shifts one nucleotide in the '1 course, from the ORF1a understanding edge into ORF1b understanding edge. This repositioning is empowered by two RNA components—a 51 - UUUAAAC-31 heptanucleotide tricky arrangement and RNA pseudoknot structure. Along these lines, polyproteins pp1a what's more, pp1ab are divided into at any rate 15 nsp, which gather and structure the replication-interpretation complex.

Table 1: SARS-CoV Vs. SARS-CoV-2

	SARS-CoV	**SARS-CoV-2**
Outbreak	2003 SARS Epidemic	2019-2020 COVID-19 Pandemic
Classification	Genus: Beta coronavirus Sub-genus: Sarbecovirus Lineage: B	Genus: Betacoronavirus Sub-genus: Sarbecovirus Lineage: B
Virus Type	+ve sense Single-stranded RNA	+ve sense Single-stranded RNA
Structure	Enveloped, spiked outer structure	Enveloped, spiked outer structure
Genome Size	Genome: approx. 29,700 bases	Genome: approx. 30kb
Protein differences		
3b protein	154 amino acids	22 amino acids
8a protein	Present	Absent
8b protein	84 amino acids	124 amino acids

With the get together of the replicase-polymerase, the full-length positive strand of genomic RNA is deciphered to frame a full-length negative-strand format for the amalgamation of new genomic RNAs and covering subgenomic negative-strand layouts. These subgenomic mRNAs

are at that point deciphered and meant to produce the auxiliary and extra proteins. A few heterologous atomic ribonucleoprotein (hnRNA) relatives (hnRNPA1, PTB, SYN-CRYP) are fundamental for proficient RNA replication. Other RNA-restricting proteins have additionally been recommended to assume a job in CoV replication, for example, m-aconitase and poly-A-coupling protein (PABP), DDX1, PCBP1/2, and zinc finger CCHC-type and RNA-restricting theme 1 (MADP1).



Fig.3. Shows replication of coronavirus SARS-CoV-2 (Source of Image NCBI BOOK)

4. Coronavirus life cycle

The superior investigation portrayal for coronavirus replication and pathogenesis has been the gathering 2 murine coronaviruses, mouse hepatitis infection, and so far of what's known about the phases of the coronavirus life cycle has been resolved in creatures and culture utilizing this infection. Accordingly, this conversation will represent considerable authority in MHV with correlations with ScoV and different coronaviruses. This is frequently appropriate in light of the fact that bioinformatics investigations suggest that ScoV, while a clear infection, has significant similitudes in the association, assumed protein capacities, and replication to the gathering II coronaviruses, fundamentally inside the replicase quality (Snijder et al., 2003). Colossal, complete audits of MHV and coronavirus replication are introduced somewhere else (Holmes and Lai, 1996; Lai and Cavanagh, 1997). The coronavirus virion is a wrapped molecule containing the spike (S), Membrane (M), envelope € proteins. Furthermore, a few strains of Coronaviruses, however not ScoV, express a hemagglutinin protein (HE) that is likewise included inside the virion. The genome of coronaviruses might be a direct, Single-abandoned RNA atom of positive (mRNA) extremity and from 28 to 32 kb during a length (Bonilla et al., 1994; Dorsten et al., 2003; Lee et al., 1991). Within the virion, the genome is embodied by numerous duplicates of the Nucleocapsid protein (N), and has the compliance of a helical RNA/nucleocapsid structure. The S protein has been consideration of pathogenesis concentrates in mice since it seems, by all accounts, to be the basic determinant of cell Tropism, species particularity, have a choice, cell tropism, and ailment (Navas and Weiss, 2003; Navas et al., 2001; Rao and Gallagher, 1998). Infection replication is started by the authoritative of the S protein to explicit

receptors on the host cell surface. For MHV, the main receptor has been demonstrated to be the carcino-early-stage antigen–cell bond atom (CEACAM) (Deviser et al., 1991; 1996; Holmes and Lai, 1996; Yokomuri and Lai, 1992), and for the human coronavirus, HcoV-229E, and other gathering 1coronaviruses, the receptor is aminopeptidase N (Yeager et al., 1992). The exact systems of passage and uncoating presently can't seem to be characterized, yet likely happen by either combination from without or viroplexis through endocytic vesicles. For wild sort, MHV, section, and uncoating establish a pH autonomous procedure that is most likely direct combination interceded by a combination peptide inside the S protein (Gallagher et al., 1991). The comprehension of the district of the S1 part of coronavirus that ties to receptors was the thought for examines bringing about the extremely later and extremely fast ID of angiotensin changing over chemical 2 (ACE 2) as a receptor for ScoV (Li et al.,2003). Ensuing discrete stage inside the existence cycle is the interpretation and proteolytic preparing of viral replicase proteins from the info genome RNA, trailed by the development of cytoplasmic replication edifices in relationship with cell films (Denison et al., 1999; Gosert et al., 2002; Shi et al., 1999; van der Meer et al., 1999). Replication buildings are believed to be destinations of all phases of viral RNA translation and replication and perhaps get together of incipient viral nucleocapsids. Viral get together happens both transiently and genuinely particular from viral replication edifices inside the endoplasmic-reticulum-Golgi-moderate compartment (ERGIC), a transitional zone between late ER and Golgi (11eVries et al., 1997; Klumperman et al., 1994; Krijnse-Locker et al., 1994; Rottier and Rose,1987). In spite of the fact that the instruments by which replication items are conveyed to locales of gathering stay to be resolved, it's been indicated those subpopulations of replicase proteins and accordingly the basic nucleocapsid (N) translocation from replication edifices to destinations of get together and should intercede the strategy in relation with cell layer/protein dealing pathways (Bost et al., 2000). The infection gets together inside the ERGIC includes associations of genome RNA, N, the film protein (M), and subsequently the little layer protein €, prompting sprouting of virions into the lumen of ER/Golgi virosomes (Opstetten et al., 1995). Further development of infection particles happens during development through the Golgi, prompting virosomes packed with developing particles (Salamuera et al., 1999). Dealing of the virosomes to the cell surface has not been all around described, however is dared to happen by means of typical vesicle development and exocytic forms. The outcome is that the non-lytic arrival of the dominant part of develops virions into the extracellular space. For MHV and various other different coronaviruses which will straightforwardly combine with cells, there's a trademark and quickly recognizable cytopathic impact of cell-cell combination into multinucleated syncytia. The creation of irresistible infection proceeds considerably after the main part of cells is intertwined. Syncytia were as of late detailed as the readout of ScoV receptor articulation and cell contamination (Li et al., 2003).

5. How does COVID -19 spread?

Individuals can get COVID-19 from other people who have the infection. The ailment spreads principally from individual to individual through little beads from the nose or mouth, which is removed when an individual with COVID-19 hacks, sniffles, or talks. These beads are generally overwhelming, don't go far and rapidly sink to the ground. Individuals can get COVID-19 in the event that they take in these beads from an individual contaminated with the infection. This is the reason it is imperative to remain at any rate of 1 meter (3 feet) away from others. These beads can arrive on articles and surfaces around the individual, for example, tables, door handles, and handrails. Individuals can get contaminated by contacting these items or surfaces, at that point contacting their eyes, nose, or mouth. This is the reason it is critical to wash your hands routinely with cleanser and water or clean with liquor based hand rub. WHO is evaluating progressing research on the ways that COVID-19 is spread and will keep on sharing refreshed discoveries.



Figure 4: Factors Related to SARS-CoV-2

If you have minor side effects, for example, a slight hack or a gentle fever, there is commonly no compelling reason to look for clinical consideration. Remain at home, self-disconnect, and screen your manifestations. Follow the national direction on self-separation. However, in the event that you live in a territory with jungle fever or dengue fever, it is significant that you don't disregard the side effects of fever. Look for clinical assistance. At the point when you go to the wellbeing office wear a cover if conceivable, keep at any rate 1-meter good ways from others, and don't contact surfaces with your hands. In the event that it is a youngster who is wiped out assistance, the kid adheres to this counsel. Seek quick clinical consideration on the off chance that you experience issues breathing or agony/pressure in the chest. On the off chance that conceivable, call your human services supplier ahead of time, so he/she can guide you to the correct wellbeing office.

6. Association between COVID-19 and creatures

SARS-CoV-2 diseases are broadly spread in the human population; there is a hazard for certain creatures to get tainted all through close contact with contaminated people. The disease of creatures with SARS-CoV-2 infection may have suggestions for creature wellbeing and government assistance, for untamed life preservation, and biomedical research. Pooches, felines (local felines and a tiger), and minks have tried positive for SARS-CoV-2 in the field

setting, following close contact with contaminated people (or people suspected to be tainted with SARS-CoV-2). Additional data about these occasions, which have answered to the OIE, can be found beneath in the 'more data' segment. Studies are in progress to more readily comprehend the helplessness of various creature species to SARS-CoV-2 and to survey contamination elements in defenseless creature species. Until now, fundamental discoveries from contemplates prompt that poultry and pigs are not defenseless to SARS-CoV-2 disease. Primer discoveries from research facility examine recommend that, of the creature species explored up until this point, felines are the most helpless species for SARS-CoV-2, and felines can be influenced with clinical sickness. In the research centers setting felines had the option to transmit contamination to different felines. Ferrets have all the earmarks of being powerless to contamination however give off an impression of being less influenced by the clinical malady. In the research centers setting ferrets were additionally ready to transmit the disease to different ferrets. Ferrets may fill in as a helpful model for future examinations for example to assess immunizations or therapeutics. Canines seem, by all accounts, to be powerless to contamination yet have all the earmarks of being less influenced than ferrets or felines. Egyptian natural product bats were additionally tainted in the research centers setting however didn't give indications of the malady. The organic product bats appeared to have the option to transmit the disease to other natural product bats.

The present spread of COVID-19 is a consequence of human to human transmission. Until now, there is no proof that friend creatures assume a critical job in spreading the infection. Accordingly, there is no legitimization in taking measures against buddy creatures that may bargain their government assistance.

7. Treatment and therapy for coronavirus

In view of a cytokine deregulation theory, the principal treatment conventions for SARS patients incorporated the organization of steroids, which was planned for balancing the exacerbated cytokine reaction, comparatively to the treatment of non-viral intense respiratory pain disorder. In any case, medicines of SARS contamination have been incapable. Medications have been founded on the organization of antibacterial (to forestall auxiliary bacterial diseases) and steroids (to balance cytokine deregulation) in blend with ribavirin (a nucleoside simple with wide antiviral action). Right now, there is no antiviral treatment for SARS infection. Endeavors have been made to concentrate in vitro defenselessness to different mixes with the potential enemy of SARS action. Be that as it may, numerous opposing discoveries have been accounted for from various labs, making it hard to accomplish a worldwide understanding about the enemy of SARS procedures. The utilization of antiviral antibodies (talked about above and underneath), passage inhibitors, proteinase inhibitors, calpain inhibitors, human immunodeficiency infection type 1 protease inhibitors, nucleoside analogs, (for example, ribavirin), interferons, and short meddling RNAs has been reported. Plasma gave from patients who had recovered from SARS has been directed as immunotherapy to SARS patients. Human gaining strength stage plasma clearly had an advantageous impact whenever managed right off the bat throughout SARS contamination. These examinations proposed that SARS hyperimmune globulin containing high titers of SARS-CoV-killing antibodies could be utilized on account of conceivable future flare-ups. The defensive adequacy of a few human monoclonal SARS-CoV-killing antibodies has been as of late exhibited utilizing different creature models (mice and ferrets). It ought to be noticed that in spite of the fact that the utilization of SARS-CoV-killing antibodies might be promising, the SARS-CoV passage could be upgraded by antibodies. Strikingly, human antibodies that killed pseudotyped lentiviruses communicating the spike glycoprotein got from most human SARS-CoV secludes upgraded passage of lentivirus pseudotyped with the palm civet spike glycoprotein.

Table 2: Comparison between Remdesivir, Chloroquine, and Lvermectin

Remdesivir	Chloroquine Hydroxychloroquine	Lvermectin
Remdesivir has been accounted for the treatment of a couple of instances of COVID-19 effectively.	Chloroquine has been used for a long time for the treatment of intestinal sickness, with an instrument not surely knew against some popular diseases.	Lvermectin is an FDA-endorsed wide range hostile to a parasitic operator that has appeared to have antiviral action against an expansive scope of infections in vitro. LIvermectin is an inhibitor of the causative infection (SARS-CoV-2) ready to impact ~a 5000-overlay decrease in viral RNA at 48 hours.
Remdesivir is a 1'-cyano-subbed adenosine nucleotide simple prodrug and shows an expansive range of antiviral movement against a few RNA infections.	It has been accepted that chloroquine can restrain pH-subordinate strides of the replication of a few infections, with an intense impact on contamination and the spread of SARS-CoV-2.	Lvermectin has been affirmed to repress atomic import and HIV-1 replication. It has been appeared to hinder the atomic import of host and viral proteins in numerous RNA infections like dengue infection (DENV), West Nile Virus, and Venezuelan equine encephalitis infection (VEEV).
A blend of remdesivir and chloroquine was demonstrated to restrain the as of late rose SARS-CoV-2 in vitro successfully	Chloroquine has immunomodulatory impacts, stifling the creation/arrival of TNF-a and IL-6 and functions as a novel class of autophagy inhibitor, which may meddle with viral contamination and replication.	This wide range movement is accepted to be because of the inclusion of IMPa/β1 during disease on account of a wide range of RNA infections. It has been expected that Lvermectin demonstrations through repressing IMPa/β1-interceded atomic import of viral proteins, as appeared for other RNA infections.
The protease inhibitors, lopinavir, and ritonavir used to treat the contamination with human immunodeficiency infection (HIV), MERS-CoV and SARS-CoV patients have been accounted for to essentially decrease the β-coronavirus viral heaps of COVID-19 patients after treatment with these medications.	Chloroquine meddled with the glycosylation of cell receptors of SARS-CoV and worked at both sections and post-passage phases of the COVID-19 contamination in Vero E6 cells.	Lvermectin has a built-up security profile for human use, and is FDA-affirmed for a few parasitic diseases and along these lines is deserving of further thought as a potential SARS-CoV-2 antiviral.

Table 3: FDA Emergency Use Authorization COVID-19 Diagnostic Tests

S.no	Diagnostic test	Company	Date	Authorized Laboratories
1	CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel	Centers for disease control and prevention	February 4, 2020, revised; March 5, 2020	Testing in the United States is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, to perform high complexity tests.
2	New York SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Panel	Wadsworth Center, New York State Department of Public Health	February 29, 2020, Revised: March 7, 2020	Qualified laboratories designated by Wadsworth Center, NYSDOH, and, in the United States, certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, to perform high complexity tests.
3	Cobas SARS-CoV-2	Roche Molecular Systems, Inc. (RMS)	March 12, 2020	United States (U.S.) in laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform moderate complexity tests and in U.S. laboratories certified under CLIA to perform high complexity tests, by clinical laboratory personnel who have received specific training on the use of the cobas 6800/8800 Systems.

4	TaqPath COVID-19 Combo Kit	Thermo Fisher Scientific, Inc.	March 13, 2020	United States (U.S.) in laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity tests.
5	Panther Fusion SARS-CoV-2	Hologic, Inc.	March 16, 2020	United States (U.S.) laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity tests.
6	COVID-19 RT-PCR Test	Laboratory Corporation of America (LabCorp)	March 16, 2020	Center of Esoteric Testing, Burlington, North Carolina, or other laboratories designated by LabCorp that are also certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity tests.
7	Lyra SARS-CoV-2 Assay	Quidel Corporation	March 17, 2020	United States (U.S.) laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity tests.
8	Quest SARS-CoV-2 rRT-PCR	Quest Diagnostics Infectious Disease, Inc.	March 17, 2020	Quest Diagnostic Laboratories or other laboratories designated by Quest Diagnostics that are also certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, to perform high complexity tests.
9	Abbott RealTime SARS-CoV-2 assay	Abbott Molecular, Inc.	March 18, 2020	Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity tests.
10	Simplexa COVID-19 Direct assay	DiaSorin Molecular LLC	March 19, 2020	Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high and moderate complexity tests.
11	ePlex SARS-CoV-2 Test	GenMark Diagnostics, Inc.	March 19, 2020	Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high and moderate complexity tests.
12	Primerdesign Ltd COVID-19 genesig Real-Time PCR assay	Primerdesign Ltd.	March 20, 2020	Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity tests.
13	Xpert Xpress SARS-CoV-2 test	Cepheid	March 20, 2020	Authorized laboratories – laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high and moderate complexity tests. Other Authorized Testing Locations – patient care settings.
14	BioFire COVID-19 Test	BioFire Defense, LLC	March 23, 2020	United States (U.S.) laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform moderate complexity tests, and in U.S. laboratories certified under CLIA to perform high complexity tests, or in similarly qualified non-U.S. laboratories.

15	Accula SARS-Cov-2 Test	Mesa Biotech Inc.	March 23, 2020	Authorized laboratories – laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high and moderate complexity tests. Other Authorized Testing Locations – patient care settings using the Accula Dock or Silaris Dock.
16	PerkinElmer New Coronavirus Nucleic Acid Detection Kit	PerkinElmer, Inc.	March 24, 2020	Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity tests.
17	AvellinoCoV2 test	Avellino Lab USA, Inc.	March 25, 2020	Testing is limited to Avellino Lab USA, Inc., which is certified under Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a to perform high complexity tests.
18	Real-Time Fluorescent RT-PCR Kit for Detecting SARS-2019-nCoV	BGI Genomics Co. Ltd.	March 26, 2020	Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 USC §263a, to perform high complexity tests.
19	NxTAG CoV Extended Panel Assay	Luminex Molecular Diagnostics, Inc.	March 27, 2020	Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 USC §263a, to perform high complexity tests.
20	ID NOW COVID-19	Abbott Diagnostics Scarborough, Inc.	March 27, 2020	Authorized laboratories – laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high and moderate complexity tests. Other Authorized Testing Locations – patient care settings using the ID NOW Instrument.
21	NeuMoDx SARS-CoV-2 Assay	NeuMoDx Molecular, Inc.	March 30, 2020	Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high and moderate complexity tests.
22	QIAstat-Dx Respiratory SARS-CoV-2 Panel	QIAGEN GmbH	March 30, 2020	Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity and moderate complexity tests.
23	qSARS-CoV-2 IgG/IgM Rapid Test	Cellex Inc.	April 1, 2020	Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, to perform moderate and high complexity tests.
24	COV-19 IDx assay	Ipsum Diagnostics, LLC	April 1, 2020	Ipsum Diagnostics, LLC, or other laboratories designated by Ipsum Diagnostics, LLC that are also certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity tests

25	BioGX SARS-CoV-2 Reagents for BD MAX System	Becton, Dickinson & Company (BD)	April 2, 2020	Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform moderate and high complexity tests.
26	ARIES SARS-CoV-2 Assay	Luminex Corporation	April 3, 2020	Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 USC §263a, to perform moderate and high complexity tests.
27	Science Cell SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCR) Detection Kit	ScienCell Research Laboratories	April 3, 2020	Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high `complexity tests.
28	Logix Smart Coronavirus Disease 2019 (COVID-19) kit	Co-Diagnostics, Inc.	April 3, 2020	Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity tests.

8. Laboratory test for the treatment of SARS-CoV-2 Or COVID-19

8.1 COVID-19 real-time SARS-CoV-2 Assay

We have so far examined the most present analytic tests that have been approved by the Food and Drugs Administration (FDA) i.e. Cepheid's Xpert Xpress SARS-CoV-2 Test and Abbott's ID NOW COVID-19 Test. The two of them meet all requirements for the quick test with each giving outcomes inside 45 minutes and 5-13 minutes individually. They apply various philosophies yet the two of them target identifying the SARS-CoV-2 RNA nucleic acids from a nasal swab or nasal wash tests. Before these two were structured, on March, eighteenth, 2020, Abbott had built up the Real-Time SARS-CoV-2 Assay. This is a mechanized Assay that sudden spikes in demand for Abbott's m2000 RealTime framework targeting distinguishing SARS-CoV-2 RNA by utilization of Real-Time Reverse Transcriptase Polymerase Chain Reaction (RT-PCR). Notwithstanding, this demonstrative test is to be utilized uniquely by research facilities ensured under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high unpredictability tests. Therefore the aim of this assay for qualitative identification of nucleic acid from the SARS-CoV-2 in nasopharyngeal (NP) and oropharyngeal (OP) swabs from patients associated with COVID-19 and the identification of COVID-19 in patients associated with COVID-19 by their medicinal services supplier.

During each round of thermal cycling, the amplification product separates to single strands at a high temperature allowing primer annealing and extension as the temperature is lowered. Exponential amplification of the product is achieved through repeated cycling between high and low temperatures, resulting in a billion-fold or greater amplification of target sequences. The amplification of the three targets (SARS-CoV-2 RdRp, SARS-CoV-2 N, and IC) takes place simultaneously in the same reaction. The target sequences for the Abbott Real-Time SARS-CoV-2 assay are in the SARS-CoV-2 RdRp and N genes of the SARS-CoV-2 genome. The selected target sequences are highly conserved and also specific to this strain of coronavirus. There are also several types of diagnostic test that are used for the treatment of COVID-19 are as follows

Table 4: Diagnostic Test for COVID-19

S.no	Diagnostic test	Purpose
1.	Serological test	Serological measures are not routinely utilized for the finding of human CoV diseases because of the absence of commercial reagents. At the point when quick antigen testing or potentially sub-atomic measures are neither accessible nor stable, serology can be utilized as an extra symptomatic device. Matched serum tests (in the intense and the improving stage) ought to be gathered as both IgM and IgG antibodies were identified five days after the beginning of contamination. There are different sorts of serological test accomplished for analysis of coronavirus: complement fixation test ELISA Haemagglutination test Immunofluorescence and so on. Viral sequencing
2.	Viral Sequencing	Viral sequencing can likewise be utilized to confirm the nearness of the infection. Besides, regular sequencing of a percentage of specimens from clinical cases can be useful to monitor the viral genome mutations that might affect the performance of medical countermeasures; including diagnostic tests. Virus whole-genome sequencing can also inform molecular epidemiology studies.
3.	Viral Culture	Infection confinement isn't suggested as a routine indicative methodology because of the absence of tolerant cell lines, time to results, work and aptitude necessities, and the absence of commercial antisera for culture confirmation. SARS-CoV and MERS-CoV and SARS-CoV-2 will develop in essential monkey cells and cell lines, for example, Vero and LLC-MK2. All things considered, cell culture ought not to be performed for suspect cases in routine analytic research centers for biosafety reasons.
4.	Rapid antigen test	Rapid antigen tests would give the benefit of quick time to results and minimal effort identification of human CoVs, notwithstanding, they are probably going to experience the ill effects of diminished affectability dependent on the involvement in this technique for other respiratory infections. The joining of colloidal gold-named immunoglobulin G (IgG) as the identification reagent is a methodology that may build the affectability of fast antigen tests for respiratory infections. Monoclonal antibodies, explicitly against SARS-CoV-2, have been under planning. Novel ways to deal with concentrate antigen, or to enhance the location stage are required if these techniques are to be utilized regularly.
5.	Plasma Therapy	ICMR has not given any clearance for its use as a prescription treatment for COVID19 and the misuse may have fatal consequences for the patients, "the Ministry added. Plasma treatment is done by taking blood plasma from a cured COVID-19 patient to treat positive cases to effectively strengthen the immune system. The Ministry had last week asked the Indian Red Cross Society (IRCS) to contact recovered COVID-19 patients to come forward for blood donation, from which convalescent plasma could be collected and used for transfusion to the COVID-19 affected patients for their early recovery.

8.2 Result Interpretation

A positive test outcome demonstrates that RNA from SARS-CoV-2 was recognized and the patient has COVID-19. In this way, all things considered, you might be put in separation to abstain from spreading the infection to other people. Correspond the positive outcomes with the patient's clinical analysis and epidemiological information when making the last conclusion and patient administration choice as per the CDC rules.

9. Concluding Remarks and Prospective:

Coronaviruses are a group of wrapped, single-abandoned, positive-strand RNA infections arranged inside the Nidovirales request. This coronavirus family comprises of pathogens of numerous creature species and of people, including the as of late separated extreme intense respiratory disorder coronavirus (SARS-CoV). This audit is isolated into two primary parts; the principal concerns the creature coronaviruses and their pathogenesis, with an accentuation on the elements of individual viral qualities, and the second talks about the recently portrayed human developing pathogen, SARS-CoV. The coronavirus part covers

I. a depiction of a gathering of coronaviruses and the maladies they cause, including the model coronavirus, murine hepatitis infection, which is one of the perceived creature models for numerous sclerosis, just as infections of veterinary significance that taint the pig, chicken, and feline and an outline of the human infections;

II. a short rundown of the replication pattern of coronaviruses in cell culture;

III. The turn of events and utilization of opposite hereditary qualities frameworks; and

IV. The jobs of individual coronavirus proteins in replication and pathogenesis. The SARS-CoV part covers the pathogenesis of SARS, the creating of creature models for disease, and the advancement in antibody improvement and antiviral treatments. The information accumulated on the creature coronaviruses keeps on being useful in understanding SARS-CoV. Therefore in present no vaccine available for this virus, in emergency clinics doctors will now and then use anti-microbials to forestall or on the other hand treat auxiliary bacterial diseases which can be an inconvenience of COVID-19 in seriously sick patients. They should just be utilized as coordinated by a doctor to treat bacterial contamination.

REFERENCES

1. Caly L, Druce J, Catton M, Jans D, and Wagstaff K. The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research. 2020. 104787. ISSN 0166-3542
2. World Health Organization Coronavirus disease 2019 (COVID-19)WHO, Geneva (2020)Situation Report 40
3. N. Zhu, D. Zhang, W. Wang, X. Li, B. Yang, J. Song, et al. A novel coronavirus from patients with pneumonia in China, 2019, N Engl J Med, 382 (8) (2020), pp. 727-733
4. M. Hoffmann, H. KleineWeber, N. Krüger, M. Müller, C. Drosten, S. PöhlmannThe novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells bioRxiv (2020)2020.01.31.929042
5. Kaye M. (2006). SARS-associated coronavirus replication in cell lines. *Emerging infectious diseases*, *12*(1)
6. Weiss, S. R., & Navas-Martin, S. (2005). Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. *Microbiology and molecular biology reviews: MMBR*, *69*(4), 635–664.
7. Weiss SR and Leibowitz JL. Chapter 4 – Coronavirus Pathogenesis. Advances in Virus Research. Academic Press. Volume 81. 2011. Pages 85-164. ISSN 0065-3527.
8. Guo Y, Cae Q, Hong Z, et al. The origin, transmission, and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Military Medical Research. (2020)
9. Fehr, A. R., & Perlman, S. (2015). Coronaviruses: an overview of their replication and pathogenesis. *Methods in molecular biology (Clifton, N.J.)*
10. Ou X, Liu Y, Lei X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nature Communications (2020)
11. Cascella M, Rajnik M, Cuomo A, et al. Features, Evaluation and Treatment Coronavirus (COVID-19) [Updated 2020 Mar 20]. In: StatPearls [Internet]. Treasure Island (FL)
12. Caly L, Druce J, Catton M, Jans D, and Wagstaff K. The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research. 2020. 104787. ISSN 0166-3542.
13. Fehr, A. R., & Perlman, S. (2015). Coronaviruses: an overview of their replication and pathogenesis. *Methods in molecular biology (Clifton, N.J.)*
14. M.L. Barreto, M.G. Teixeira, E.H. CarmoInfectious diseases epidemiology
15. J Epidemiol Community Health, 60 (2006), pp. 192-195
16. Zhang, W. Zheng, X. Huang, E.W. Bell, X. ZhouZhang Y. Protein structure and sequence re-analysis of 2019-nCoV genome does not indicate snakes as its intermediate host or the unique similarity between its spike protein insertions and HIV-1
17. J Proteome Res, 19 (4) (2020), pp. 1351-1360
18. P.K. Chan, J.W. Tang, D.S. Hui SARS: clinical presentation, transmission, pathogenesis and treatment options Clin Sci, 110 (2006), pp. 193-204
19. Y. Yang, Q. Lu, M. Liu, Y. Wang, A. Zhang, N. Jalali, et al. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China med Riv, 2020 (2020)2020.02.10.20021675
20. M. Wang, R. Cao, L. Zhang, X. Yang, J. Liu, M. Xu, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
21. Cell Res, 30 (3) (2020), pp. 269-271
22. J. Gao, Z. Tian, X. YangBreakthrough: Chloroquine phosphate has shown apparent efficacy in the treatment of COVID-19 associated pneumonia in clinical studies Biosci Trends, 14 (1) (2020), pp. 72-73
23. H. LuDrug treatment options for the 2019-new coronavirus (2019-nCoV)Biosci Trends, 14 (1) (2020), pp. 69-71
24. Akerstrom, S., M. Mousavi-Jazi, J. Klingstrom, M. Leijon, A. Lundkvist, and A. Mirazimi. 2005. Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus. J. Virol. 79:1966–1969.
25. R. Lu, X. Zhao, J. Li, P. Niu, B. Yang, H. Wu, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Lancet (2020)

26. D.K.W. Chu, Y. Pan, S.M.S. Cheng, K.P.Y. Hui, P. Krishnan, Y. Liu, et al. Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia
27. Clin Chem (2020)
28. Y.H. Jin, L. Cai, Z.S. Cheng, H. Cheng, T. Deng, Y.P. Fan, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)Mil Med Res, 7 (1) (2020)